PSA-based prostate cancer screening: The role of active surveillance and informed and shared decision making

Asian Journal of Andrology

Volumn 13, Issue 2, 2011, Pages 219-224

  Venderbos, Lionne D F ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

active surveillance; informed decision making; PSA testing; shared decision making

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; DECISION MAKING; DIAGNOSTIC TEST; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

CONSUMER HEALTH INFORMATION; DECISION MAKING; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; WATCHFUL WAITING;

EID: 79952410093     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.180     Document Type: Review

References (62)

1. Bangma CH. Indolent prostatecancerand activesurveillance. Cancer World January-February 2010: 15-21.
2. van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospectivevalidation of activesurveillance in prostatecancer: the PRIASstudy. Eur Urol 2007; 52: 1560-3.
3. Flocks RH, Urich VC, Patel CA, Opitz JM. Studies on the antigenic properties of prostatic tissues. J Urol 1960; 84: 134-43.
4. Kouriefs C, Sahoyl M, Grange P, Muir G. Prostate-specific antigen through theyears. Arch Ital Urol Androl 2009; 81: 195-8.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 2009; 360:1320-8.
6. Andriole GL,Crawford ED, Grubb RL3rd, Buys SS, Chia Det al. Mortalityresultsfroma randomized prostate-cancerscreeningtrial. New Engl J Med 2009; 360: 1310-9.
7. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami Aet al. Mortalityresultsfromthe Göteborgrandomised population-based prostate-cancerscreeningtrial. Lancet Oncol 2010; 11: 725-732.
8. Costanza ME, Luckmann RS, Rosal M, White MJ, Lapelle N et al. Helping men make an informed decision about prostate cancer screening: a pilot study of telephone counselling. Patient Educ Couns; e-pub ahead of print 14 January 2010; doi: 10.1016/j.pec. 2010.05.011.
9. Schröder FH. Reviewof diagnosticmarkersforprostatecancer. Recent Results Cancer Res 2009; 181: 173-82.
10. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. New Engl J Med. 2004, 350, 2239-46.
11. Evans R, Edwards AG, Elwyn G, Watson E, Grol R et al. 'It's a maybe test': men's experiencesof prostate-specificantigentesting in primarycare. Br J Gen Pract 2007; 57: 303-10.
12. Rai T, Clements A, Bukach C, Shine B, Austoker J et al. What influences men's decision to have a prostate-specific antigen test? A qualitative study. Fam Pract 2007; 24: 365-71. (Pubitemid 47399894)
13. Ferlay JBF, Pisani P, Parkin DM. GLOBOCAN 2002. Cancerincidence, mortalityand prevalence worldwide.Version 1.0. IARCCancer Baseno. 5. Lyon: IARC Press; 2004.
14. Klotz L Active surveillance for prostate cancer: patient selection and management. Curr Oncol7 2010; Suppl 2, S11-7.
15. Challacombe BJ, Murphy D, Lilja H, Vickers AJ, Costello AJ. The continuing role of prostate-specific antigen as a marker for localized prostatecancer: 'do notthrowthe baby out with the bath water'. BJU Int 2009; 104: 1553-4.
16. Hayes JH,Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW et al. Activesurveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-80.
17. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostatecancer. J Clin Oncol 1999;17:168-72. (Pubitemid 29022390)
18. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78. (Pubitemid 36833878)
19. Van Den Bergh RC, Vasarainen H, vander Poel HG, Vis-Maters JJ, Rietbergen JB et al. Short-term outcomes of the prospective multicenter 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010; 105: 956-62.
20. Roemeling S, Roobol MJ, Postma R, Gosselaar C, vander Kwast TH et al. Management and survival of screen-detected prostatecancer patientswho might have been suitable for active surveillance. Eur Urol 2006; 50: 475-82. (Pubitemid 44189069)
21. Parker C Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-6. (Pubitemid 38145893)
22. van Vugt HA, Bangma CH, Roobol MJ. Should prostate-specific antigen testing be offered to asymptomatic men? Expert Rev Anti Cancer Ther 2010; 10: 1043-53.
23. Klotz L, Zhang L, Lam A, Nam R, Mamedov Aet al. Clinical resultsof long-termfollow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31.
24. Carter HB, Walsh PC, Landis P, Epstein IJ. Expectant management of nonpalpable prostatecancer with curative intent: preliminary results. J Urol 2002: 167: 1231-4. (Pubitemid 34132060)
25. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P et al. Expectantmanagement of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178: 2359-64; discussion 2364-5.
26. Kakehi Y, Kamoto T, Shiraishi T,Ogawa O, Suzukamo Yet al. Prospectiveevaluationof selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008; 38: 122-8. (Pubitemid 351337956)
27. Roemeling S, Roobol MJ, deVries SH, Wolters T, Gosselaar C et al. Activesurveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSAdoublingtimes, and outcome. Eur Urol 2007; 51: 1244-51. (Pubitemid 46436308)
28. Klotz L, Kibel A, Sanda M. Observation of radical treatment in patients with prostate cancer. US National Institutes of Health, Clinical Trials.gov: NCT00499174. 2007.
29. van den Bergh RC, van Vugt HA, Korfage IJ, Steyerberg EW, Roobol MJ et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int 2010; 105: 322-8.
30. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schröder FH et al. Anxiety and distress duringactivesurveillance for early prostate cancer. Cancer 2009; 115: 3868-78.
31. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schröder FH, Bangma CH et al. Do anxietyand distress increaseduringactivesurveillancefor lowriskprostatecancer? J Urol 2010; 183: 1786-91.
32. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003; 30: 303-9.
33. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL et al. The relationship between anxietyandtimetotreatmentfor patientswith prostatecanceron surveillance. J Urol 2007; 178: 826-31.
34. Patel MI, De Concini DT, Lopez-Corona E, Ohori M, Wheeler T et al. Ananalysisof men withclinically localized prostatecancer whodeferred definitive therapy. J Urol 2004; 171: 1520-4. (Pubitemid 38365409)
35. Avery KN, Blazeby JM, Lane JA, Neal DE, Hamdy FC et al. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol 2008; 53: 1186-93. (Pubitemid 351615449)
36. Dale W, Basu A, Elstein A, Meltzer D. Predicting utility ratings for joint health states fromsinglehealthstatesinprostatecancer: empiricaltestingof 3alternativetheories. Med Decis Making 2008; 28: 102-12.
37. Korfage IJ,vanden Bergh RC, Essink-Bot ML. Decidingon PSA-screening\qualityof current consumer information on the internet. Eur JCancer 2010. 46. 3073-81.
38. Allen JD, Othus MK, Hart A Jr, Mohllajee AP, Li Y et al. Do men make informed decisions about prostate cancer screening? Baseline results from the 'Take the Wheel'Trial. Med Decis Making 2010 May 18.
39. Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P et al. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. J Med Internet Res 2010; 12: e27.
40. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect 2001; 4: 99-108. (Pubitemid 32464021)
41. van Vugt HA, Roobol MJ, Venderbos LD, Joosten-vanZwanenburg E, Essink-Bot MLet al. Informed decision makingon PSAtesting for thedetection of prostatecancer: an evaluation of a leaflet with risk indicator. Eur J Cancer 2010; 46: 669-77.
42. Nijs HG, Essink-Bot ML, deKoning HJ, Kirkels WJ,Schröder FH.Whydomen refuseor attend population-based screening for prostate cancer? J Public Health Med 2000; 22: 312-16.
43. Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol 2001; 165: 445-54. (Pubitemid 32060434)
44. Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result Br JCancer 2010; 102: 1335-40.
45. Woolf SH, Krist A. Shared decision makingfor prostatecancer screening: do patients or clinicians havea choice? Arch Intern Med 2009; 169: 1557-9.
46. Partin MR, Nelson D, Radosevich D, Nugent S, Flood AB et al. Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences and behaviors. JGen Intern Med 2004; 19: 835-42. (Pubitemid 39096355)
47. Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test J Gen Intern Med 2001; 16: 391-8. (Pubitemid 34205657)
48. Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med 2003; 18: 781-7. (Pubitemid 37281771)
49. Taylor KL, Davis JL3rd, Turner RO, Johnson L, Schwartz MD et al. Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer Epidemiol Biomarkers Prev 2006; 15: 2179-88. (Pubitemid 44877044)
50. Myers RE, Daskalakis C, Cocroft J, Kunkel EJ, Delmoor E et al. Preparing African-American men in communityprimarycare practicesto decide whether or notto have prostatecancer screening. J Natl Med Assoc 2005; 97: 1143-54. (Pubitemid 41098542)
51. O'Conner AM, Fiset V, De Grasse C, Graham ID, Evans W et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Inst Monogr 1999:7-80.
52. Gattellari M, Ward JE. Does evidence-based information about screeningfor prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screen 2003; 10: 27-39. (Pubitemid 36560965)
53. Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med 2003; 1: 22-8.
54. Krist AH, Woolf SH, Johnson RE, Kerns JW. Patient education on prostate cancer screeningand involvement in decision making. Ann Fam Med 2007; 5: 112-9. (Pubitemid 46513479)
55. Hoffman RM, Couper MP, Zikmund-Fisher BJ, Levin CA, Mc Naughton-Collins M et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med 2009; 169: 1611-8.
56. Shepherd HL, Butow PN, Tattersall MH. Factors which motivate cancer doctors to involvetheir patients in reachingtreatmentdecisions. Patient Educ Couns 2010 Nov 25.
57. Davison BJ, Degner LF. Empowerment of men newlydiagnosed with prostatecancer. Cancer Nurs 1997; 20: 197-96.
58. Davison BJ, Degner LF, Morgan TR. Information and decision-making preferences of men with prostatecancer. Oncol Nurs Forum 1995; 22: 1401-8.
59. Steginga SK, Pinnock C, Jackson C, Gianduzzo T. Shared decision-making and informed choice for the early detection of prostate cancer in primary care. BJU Int 2005; 96: 1209-10. (Pubitemid 41743907)
60. Lim LS, Sherin K, Committee APP. Screening for prostate cancer in U.S. men ACPM position statementon preventive practive. Am J Prev Med 2008; 34: 164-70.
61. Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 2008; 149: 185-91.
62. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AVet al. American Cancer Societyguidelinefortheearlydetectionof prostatecancer: update 2010. CA Cancer J Clin 2010; 60: 70-98.